---
title: "Rallybio | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 212 K"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286309570.md"
datetime: "2026-05-13T20:08:44.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286309570.md)
  - [en](https://longbridge.com/en/news/286309570.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286309570.md)
---

# Rallybio | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 212 K

Revenue: As of FY2026 Q1, the actual value is USD 212 K, beating the estimate of USD 0.

EPS: As of FY2026 Q1, the actual value is USD -1.46.

EBIT: As of FY2026 Q1, the actual value is USD -8.934 M.

Rallybio Corporation operates as a single reporting segment, with its financial performance primarily driven by research and development activities and strategic transactions .

#### Revenue

-   Collaboration and license revenue remained constant at $212 thousand for both the three months ended March 31, 2026, and March 31, 2025 .

#### Operating Expenses

-   Total operating expenses decreased to $8,945 thousand for the three months ended March 31, 2026, from $9,882 thousand for the same period in 2025 .
-   Research and development expenses decreased by $2,854 thousand, from $5,725 thousand in 2025 to $2,871 thousand in 2026 .
    -   RLYB212 development costs decreased by $2,382 thousand, from $2,438 thousand in 2025 to $56 thousand in 2026, primarily due to the discontinuation of the FNAIT program .
    -   RLYB116 development costs decreased by $223 thousand, from $619 thousand in 2025 to $396 thousand in 2026, mainly due to a decrease in manufacturing costs .
    -   Personnel expenses within R&D decreased by $309 thousand, from $2,589 thousand in 2025 to $2,280 thousand in 2026, attributed to lower headcount and reduced share-based compensation, partially offset by increased severance related to the terminated merger .
-   General and administrative expenses increased by $1,917 thousand, from $4,157 thousand in 2025 to $6,074 thousand in 2026, primarily due to a $2.7 million increase in legal and professional fees associated with the terminated merger .
    -   This increase was partially offset by an $800 thousand decrease in personnel expenses, related to lower headcount and reduced share-based compensation, though severance from the terminated merger increased .

#### Other Income and Loss

-   Total other income, net, decreased by $363 thousand, from $818 thousand in 2025 to $455 thousand in 2026, mainly due to lower interest income from marketable securities .
-   Loss on investment in joint venture was $0 for the three months ended March 31, 2026, compared to $587 thousand in 2025, as Rallybio Corporation sold its interest in REV102 in July 2025 .

#### Net Loss

-   Net loss improved to - $8,278 thousand for the three months ended March 31, 2026, from - $9,439 thousand for the same period in 2025 .
-   Accumulated deficit as of March 31, 2026, was - $310.3 million .

#### Liquidity and Capital Resources

-   Cash, cash equivalents, and marketable securities totaled $46.8 million as of March 31, 2026 .
-   Net cash used in operating activities was - $7,978 thousand for the three months ended March 31, 2026, compared to - $10,205 thousand for the same period in 2025, driven by decreased R&D activities offset by increased G&A .
-   Net cash provided by investing activities was $17,900 thousand for the three months ended March 31, 2026, compared to $11,081 thousand for the same period in 2025 .
-   Net cash provided by financing activities was $3 thousand for the three months ended March 31, 2026, from stock option exercises .

#### Future Outlook and Strategy

Rallybio Corporation expects its existing cash, cash equivalents, and marketable securities to fund operating expenses and capital requirements for more than 12 months from the financial statements’ issuance date . However, current capital is not anticipated to be sufficient to fund any product candidates through regulatory approval, necessitating substantial additional capital for development and commercialization . The company plans to focus near-term R&D efforts on completing ongoing activities and preparing programs for potential transactions or sales . Following a terminated merger agreement, Rallybio Corporation received a $50.0 million termination fee and $0.4 million reimbursement for expenses on May 4, 2026 .

### Related Stocks

- [RLYB.US](https://longbridge.com/en/quote/RLYB.US.md)

## Related News & Research

- [Are SUNE, RLYB, ASRT, TMHC Obtaining Fair Deals for their Shareholders?](https://longbridge.com/en/news/289222291.md)
- [Rallybio (NASDAQ:RLYB) Major Shareholder Adar1 Capital Management, Llc Acquires 800 Shares](https://longbridge.com/en/news/286420443.md)
- [12:15 ETShareholder Alert: Ademi LLP investigates whether Rallybio Corporation is obtaining a Fair Price for Public Shareholders](https://longbridge.com/en/news/288455561.md)
- [Shoppers Are More Selective, Not Pulling Back, Says G-III](https://longbridge.com/en/news/288896724.md)
- [Dogecoin Down 21% In A Month: What Is Going On With DOGE?](https://longbridge.com/en/news/289061120.md)